CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Call for Patient Input and Clinical Experts: Dupixent

Published on: September 23, 2019
Result type: News

CADTH has received the following notice(s) of pending drug submission(s).

Brand name Dupixent
Generic name dupilumab
Manufacturer Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
Indication(s) atopic dermatitis
Project Number SR0636-000
Call for patient input 2019-09-23
Patient input deadline 2019-11-12
Submit patient input Submit
Register as Clinical Expert Register